2014 Archived Content

Antibodies for Cancer Therapy


Day 1 | Day 2 | Download Brochure | Speaker Bios 

Scientific Advisory Board
Soldano Ferrone, M.D., Ph.D., Lecturer, Surgical Oncology, Surgery, Massachusetts General Hospital
Mitchell Ho, Ph.D., Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH
Horacio G. Nastri, Ph.D., Director Biotherapeutics, Center for Therapeutic Innovation (CTI), Pfizer, Inc
.

MONDAY, MAY 5


RECOMMENDED PRE-CONFERENCE SHORT COURSES*

Translational Strategies for Development of Monoclonal Antibodies from Discovery to Clinic, Part 1: Focus on Early Discovery & Part 2: Focus on Nonclinical Development to Clinic - View Detailed Agenda 

*Separate registration required


7:00 am Registration and Morning Coffee

Plenary Keynote Session

8:30 Chairperson’s Opening Plenary Remarks

Kristi Sarno, Chair, Greater Boston Chapter, Women in Bio; Director, Business Development, Pfenex, Inc.

8:40 Harnessing the Patient’s Immune System to Combat Cancer

Peter CR Emtage, Ph.D., Vice President, Immune Mediated Therapies, MedImmune

With recent FDA approvals, modulation of the immune system is now a clinically validated approach in the treatment of some cancers. At MedImmune, the Oncology Department is developing assets and expertise in Immune Mediated Therapy of Cancer (IMT-C). The challenges from a drug development perspective are multi-fold. The talk will focus on the relevance of preclinical models and translational science to address key issues, including dose selection and rationale combinations.

9:25 Building Regeneron’s Pipeline: From Trap Technology to the VelocImmune Platform to Veloci-Next

George D. Yancopoulos, M.D., Ph.D., President, Regeneron Laboratories; CSO, Regeneron Pharmaceuticals, Inc.

George D. Yancopoulos will discuss how he and his colleagues exploited a commitment to science and technology to start the company, withstand years of challenges and failures, and emerge with a pipeline of promising technologies and novel/biologics that are beginning to bring hope to countless patients and their families.

10:10 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing


Trends in Immunotherapy 

11:05 Chairperson's Remarks

SoldanoFerroneSoldano Ferrone, M.D., Ph.D., Lecturer, Surgical Oncology, Surgery, Massachusetts General Hospital





11:10 Glass Half-Empty or Half-Full? Potential Mechanisms of Non-Response to Immunomodulatory Antibodies

PiearceABCRobert H. Pierce, M.D., CMO, OncoSec Medical, Inc.





11:40 Mechanisms by Which Tumor Antigen-Specific Antibodies Enhance and Skew Tumor Antigen-Specific Cellular Immune Responses

Neil Gildener-Leapman, M.D.,Instructor, Department of Otolaryngology, University of Pittsburgh Medical Center

This talk will describe the ability of tumor antigen targeted mAb to enhance cellular immunity, to skew the T lymphocyte response in the tumor microenvironment, with implications for novel combination therapeutic strategies.


12:10 pm Selected Poster Presentation: Chemically Programmed Bispecific Antibodies in DART Format

Even Walseng, Ph.D., Senior Research Associate, Cancer Biology, The Scripps Research Institute

12:25 Selected Poster Presentation: Annotation of the Heavy Chain Immunoglobulin Gene Locus in Cynomolgus Monkeys by High-Throughput Antibody Repertoire Sequencing

Ina Hellmann, Ph.D., Department of Biosystems Science and Engineering, ETH Zürich
 

12:40 Enjoy Lunch on Your Own

1:40 Session Break

2:00 Chairperson's Remarks

Soldano Ferrone, M.D., Ph.D., Lecturer, Surgical Oncology, Surgery, Massachusetts General Hospital


2:05 Antibodies as Mediators of Anti-Tumor Immunity

Robert A. Anders, M.D., Ph.D., Associate Professor, Pathology, Johns Hopkins School of Medicine

We have developed a functional proteomics approach to identify antibody targets of the immune response. Using immunized sera from patients responding to immunotherapy, we have identified a panel of antigenic and tolerating proteins and have studied their role in preclinical models. These data and their clinical and diagnostic implications will be discussed.
 

2:35 Keynote Presentation:

Recent Advances in Cancer Immunotherapy

Michael AtkinsMichael B. Atkins, M.D., Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center; Professor, Oncology and Medicine, Georgetown University Medical Center

This talk will cover the immune checkpoints CTLA-4 and PD-1. Antibodies targeting these molecules, used alone or in combinations, can restore anti-tumor immunity and produce rapid and sustained tumor responses in patients with a variety of advanced malignancies leading to broad-based clinical development efforts.

3:05 PD-1 Immunotherapy

GordonFreemanGordon Freeman, Ph.D., Associate Professor, Medicine, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School





3:35 Novel MHC I Antibody Fusions for Cancer Treatment

HendrikKnoetgenHendrik Knoetgen, Ph.D., Head, LMR Penzberg & pRED, Roche Diagnostics GmbH

Here we describe a novel recombinant format of viral peptide-MHC I IgG fusion proteins. Our results show for the first time that recombinant pMHC I full length antibody fusions successfully recruit pre-existing virus specific CD8+ T cells from human PBMCs and effectively trigger eradication of the targeted tumor cells.

4:05 Refreshment Break in the Exhibit Hall with Poster Viewing

 


4:45 Problem Solving Breakout Discussions 

These interactive discussion groups are open to all attendees, speakers, sponsors, & exhibitors. Participants choose a specific breakout discussion group to join. Each group has a moderator to ensure focused discussions around key issues within the topic. This format allows participants to meet potential collaborators, share examples from their work, vet ideas with peers, and be part of a group problem-solving endeavor. The discussions provide an informal exchange of ideas and are not meant to be a corporate or specific product discussion. 

Targeting Cancer Stem Cells with Antibodies 

Christopher L. Reyes, Ph.D., Vice President, R&D, Biologics, Bionomics, Inc. 

• Discuss opportunities such as multiple important cell-surface expressed CSC targets, for treating most cancers
• Discuss challenges such as complex signaling pathways; multiple receptors and ligands
• Targeting normal stem cells raises safety/toxicity issues
• Poorly characterized CSC receptors
• Generating high affinity, quality antibodies against new receptors can be challenging
• Identifying functional antibodies with CSC specific assays
 

ADCC-Enhanced Antibodies 

Christian Klein, Ph.D., Discovery Oncology oDTA, Pharma Research and Early Development (pRED), Roche Glycart AG 

• Technologies for Fc-, glycoengineering
• ADCC-enhanced antibodies in development
• Future developments
• Role of FcRn engineering
 

PD-1 Immunotherapy 

Gordon Freeman, Ph.D., Associate Professor, Medicine, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School   
• How does the blockade of PD-1 signaling improve the in vitro proliferation of HCV-specific T lymphocytes?
• Can antiviral function be restored in infected individuals?
• What do the results of PD-1 immunotherapy suggest?
 

Tumor Antigen-Specific Antibody-Based Immunotherapy of Malignant Disease, Cancer Initiating Cells and Disease Recurrence 

Soldano Ferrone, M.D., Ph.D., Lecturer, Surgical Oncology, Surgery, Massachusetts General Hospital
• What are the characteristics of cancer initiating cells (CICs)?
• What are the markers used for their identification in various types of cancers?
• What does the evidence suggest?
• Potential strategies to overcome the resistance
 

Therapeutic Antibodies Targeting WNT and Other Signaling Pathways in Cancer 

Mitchell Ho, Ph.D., Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH
         
• Role of Wnt and other key signaling pathways in cancer pathogenesis
• Identification of new and emerging cell surface signaling molecules
• Functional analysis of therapeutic antibodies in cancer cells
 


 
 


5:45 Welcome Reception in the Exhibit Hall with Poster Viewing

6:45 End of Day


Day 1 | Day 2 | Download Brochure | Speaker Bios